Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP: Intensive vs Standard SBP Control in Elderly Hypertensive Patients
NCT03015311Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jan 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of olmesartan and amlodipine in hypertension (HTN) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Primary composite outcome (Stroke, ACS, HF, Coronary revascularization, AF, CV death) at 4 years. Status: unknown.
02
Drugs
olmesartanamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03015311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015311.